DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Luteal Phase Progesterone in IUI and Gonadotropin Cycles

Information source: University of Alberta
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infertility

Intervention: Progesterone Effervescent Vaginal Tablets (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: University of Alberta

Overall contact:
Tarek Motan, MB ChB, Phone: 780-735-5604, Email: tmotan@ualberta.ca


This is a study of patients undergoing Controlled Ovarian Hyperstimulation (COH) with Gonadotropins and Intrauterine Insemination (IUI) at a Fertility Clinic. Infertility is a common problem, and a popular method of therapy is to inject sperm through the cervix and into the uterus, a procedure known as IUI. In conjunction with IUI, injectable medications (gonadotropins) are used to stimulate the ovaries to produce more than one egg per cycle in a process called COH. Vaginal progesterone is used for luteal support in in vitro fertilization therapy and has been proven to effect pregnancy rates. However, the role of progesterone in COH is still unclear. In this study, the investigators want to examine the effect of giving vaginal progesterone after COH with IUI on pregnancy rates. The investigators want to study if luteal vaginal progesterone results in a higher pregnancy rate compared to no progesterone therapy in COH with IUI. At present, fertility centres vary in the use of progesterone after insemination, most likely due to the lack of studies on this subject. At the Fertility Clinic all patients undergoing COH with injectable medications and IUI, regardless of whether they are in the study, have a baseline transvaginal ultrasound and blood tests. Patients start the injectable medications for COH until the ovarian follicles are large enough, then a medication to release the eggs is given. The IUI is done approximately 36 hours later. The day after the IUI, study patients will be given vaginal progesterone while the control patients will receive no progesterone. All patients will be followed until a pregnancy test is done and a viable foetus is confirmed by ultrasound.

Clinical Details

Official title: The Effect of Luteal Phase Support on Pregnancy Rate in Intrauterine Insemination Cycles Following Ovarian Stimulation With Gonadotropins

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Clinical pregnancy rate

Secondary outcome:

Biochemical Pregnancy

Non-viable Pregnancy

Multiple Pregnancy


Minimum age: 21 Years. Maximum age: 43 Years. Gender(s): Female.


Inclusion Criteria:

- Couples with infertility

- Confirmed bilateral tubal patency

- More than 10 million motile sperm available for IUI

Exclusion Criteria:

- Subjects declining enrollment

- Allergies to prescribed vaginal progesterone

- Subjects less than 21 years old or over 43 years old

Locations and Contacts

Tarek Motan, MB ChB, Phone: 780-735-5604, Email: tmotan@ualberta.ca

Fertility & Womens Endocrine Clinic, Royal Alexandra Hospital, Edmonton, Alberta T5H 3V9, Canada; Recruiting
Tarek Motan, MB ChB, Phone: 780-735-5604, Email: tmotan@ualberta.ca
Jinglan Han, MD, Phone: 780-735-5604, Email: jinglan@ualberta.ca
Tarek Motan, MB ChB, Principal Investigator
Jinglan Han, MD, Sub-Investigator
Additional Information

Starting date: July 2014
Last updated: December 31, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017